KI-20227 is a potent and orally active inhibitor of c-Fms tyrosine kinase (M-CSFR, CSF1R) (IC50 values are 2, 12, 217 and 451 nM for c-Fms, VEGFR-2, PDGFRbeta and c-Kit respectively). KI-20227 suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. KI-20227 inhibits disease progression in a collagen-induced arthritis mouse model. KI-20227 suppresses experimental autoimmune encephalomyelitis.
Buffer:
Powder
CAS Number:
[623142-96-1]
* VAT and and shipping costs not included. Errors and price changes excepted
